Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.

Voziyan PA, Hudson BG
Cell Mol Life Sci. 2005 62 (15): 1671-81

PMID: 15905958 · DOI:10.1007/s00018-005-5082-7

The discovery that pyridoxamine (PM) can inhibit glycation reactions and the formation of advanced glycation end products (AGEs) stimulated new interest in this B6 vitamer as a prospective pharmacological agent for treatment of complications of diabetes. The mechanism of action of PM includes: (i) inhibition of AGE formation by blocking oxidative degradation of the Amadori intermediate of the Maillard reaction; (ii) scavenging of toxic carbonyl products of glucose and lipid degradation; and (iii) trapping of reactive oxygen species. The combination of these multiple activities along with PM safety posture it as a promising drug candidate for treatment of diabetic complications as well as other multifactorial chronic conditions in which oxidative reactions and carbonyl compounds confer pathogenicity.

MeSH Terms (8)

Animals Diabetes Complications Glycation End Products, Advanced Humans Maillard Reaction Oxidative Stress Pyridoxamine Reactive Oxygen Species

Connections (3)

This publication is referenced by other Labnodes entities: